Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferric subsulfate is a topical hemostatic (stypic) agent used to control minor bleeding after superficial surgical procedures such as shave, punch, or cervical biopsies. It acts by causing agglutination and denaturation of surface proteins (such as fibrinogen) through the action of ferric ions and its highly acidic pH, resulting in rapid local hemostasis—typically within 20 seconds of application. The drug is only for external use and should not be ingested or applied to the eyes. Commonly known as Monsel’s solution or Astringyn, it may cause persistent hyperpigmentation at the site of application due to deposition of ferric salts in tissue[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferric subsulfate.